

First dose-ranging study of remimazolam in Japanese patients undergoing gastrointestinal endoscopy: Phase II investigator-initiated clinical trial. *Dig Endosc.* 2022 May 25.

本研究は、レミマゾラムという新規ベンゾジアゼピン系鎮静薬に関する医師主導治験 phase2 の結果になります。今まで日本では、保険収載された適切な鎮静薬がなく、内視鏡鎮静ガイドラインでも大きな問題となっておりました。PMDA との交渉を入れると 4 年間の歳月がかかり多くの先生方のご指導のもと完成した論文です。Digestive Endoscopy (IF; 6.3)に掲載されました。

下記リンクより原文をご覧ください。

<https://onlinelibrary.wiley.com/doi/10.1111/den.14365>

The screenshot shows the Wiley Online Library interface. At the top, there is a navigation bar with the Wiley Online Library logo, a search bar, and a 'Login / Register' link. Below the navigation bar, there is a banner for 'Call For Papers on Quality control and education in endoscopy' with a 'Submit Now' button and a deadline of June 30, 2023. The main content area features the article title 'First dose-ranging study of remimazolam in Japanese patients undergoing gastrointestinal endoscopy: Phase II investigator-initiated clinical trial' by Ryoji Ichijima, Hisatomo Ikehara, Takeshi Maeda, Tomomi Sugita, Toshiaki Horii, Aya Iwao, Kanako Ogura, Chika Kusano, Yuko Kondo, Takahiro Suzuki, and Takeji Gotoda. The article is published in *Digestive Endoscopy* (DEN) and is available as an 'Early View'. The page includes a 'Read the full text' button, a PDF icon, and a 'SHARE' button. The 'Abstract' section is visible, starting with 'Objectives' and describing the study's purpose: 'Remimazolam, an ultra-short-acting benzodiazepine, has been used for procedural sedation in the United States. We conducted an investigator-initiated clinical trial to determine the appropriate dose of remimazolam required for sedation during gastrointestinal endoscopy in Japanese subjects.' A 'Recommended' section on the right side of the page lists related articles, including 'Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy' and 'Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non-inferiority, phase III trial'.